Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

472.200
-14.800-3.04%
Volume:349.28K
Turnover:164.29M
Market Cap:112.86B
PE:-285.00
High:500.000
Open:500.000
Low:459.000
Close:487.000
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.70
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.657
ROE:2.92%
ROA:-0.04%
PB:18.06
PE(LYR):-285.00
PS:46.21

Loading ...

UBS Lifts SKB BIO Price Target to HK$678 on Strong First-Half Profit Beat

Stock News
·
Aug 18

Switzerland's Basilea H1 Revenue Rises on Cresemba Demand; Ups 2026 Profit Outlook

Reuters
·
Aug 18

Hong Kong Stock Flash | Kelun-Biotech (06990) Surges Over 4% Pre-Noon as Commercial Product Portfolio Scales Up, H1 Product Sales Double Year-on-Year

Stock News
·
Aug 18

Movement Alert|SKB BIO Rises 3.25% in Regular Trading, H1 Swing to Profit with Net Income Reaching 388 Million Yuan

Market Focus
·
Aug 18

Humanoid Robot Output Ramps Up as Oil and Gas 15th Five-Year Plan Takes Shape

Stock News
·
Aug 18

Vaccine Maker Sinovac H1 Revenue Rises on Overseas Growth, Approvals

Reuters
·
Aug 17

SKB Biopharma Turns to H1 Profit

MT Newswires Live
·
Aug 17

SKB BIO (06990) Delivers on Both Performance and Innovation, Marking Its Biopharma Ascent

Stock News
·
Aug 17

China's Sichuan Kelun-Biotech Swings to Profit in H1 on New Product Approvals

Reuters
·
Aug 17

Sichuan Kelun-Biotech Biopharmaceutical Posts HY Net Income Attributable of RMB 388 MLN

Reuters
·
Aug 17

Press Release: Kelun-Biotech Announces 2026 Interim Results

Dow Jones
·
Aug 17

Sichuan Kelun-Biotech H1 Revenue RMB 978.3 Million

THOMSON REUTERS
·
Aug 17

Sichuan Kelun-Biotech H1 Net Income Attributable RMB 388 Million

THOMSON REUTERS
·
Aug 17

Kelun-Biotech Returns to Profit with FY26 H1 Net Income RMB 388.01 Million; Revenue Rises 2.9% to RMB 978.34 Million

Reuters
·
Aug 17

Movement Alert|SKB BIO Rises 3.15% in Regular Trading, Dual-Payload ADC Drug SKB565 Approved for Clinical Trials Ahead of Interim Results Review

Market Focus
·
Aug 07

Is Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Cheap As ADC Pipeline News Builds?

Simply Wall St.
·
Aug 06

Global AI Competition Heats Up, Commodity Stocks Rally in Hong Kong Markets

Stock News
·
Aug 06

Hong Kong Stock Moves: SKB BIO Surges Over 4% Before Noon as New Dual-Load ADC Drug Gets Clinical Trial Approval

Stock News
·
Aug 06

Movement Alert|SKB BIO Rises 3.4% in Regular Trading, Interim Results Review Approaching Amid Pipeline Catalysts

Market Focus
·
Aug 06

SKB BIO Sets 17 Aug 2026 Board Meeting to Approve 1H26 Interim Results; Announces Same-Day Webcast

Bulletin Express
·
Aug 05